Cello World Limited reports unaudited Q2 FY27 results

Cello World Limited announced its unaudited standalone and consolidated financial results for the second quarter and six months ended September 30, 2026. The results were approved by the Board of Directors on November 05, 2026. A limited review report from Deloitte Haskins & Sells LLP is also included, detailing the financial performance for the period.

Financial Results for Q2 FY27 Announced

Cello World Limited has officially released its unaudited financial results for the quarter and six months that concluded on September 30, 2026. These results encompass both standalone and consolidated financial statements.

Board Approval and Audit Review

The financial results received approval from the Board of Directors of Cello World Limited during their meeting held on November 05, 2026. Furthermore, a limited review of these standalone and consolidated unaudited financial results was conducted by the statutory auditors, Deloitte Haskins & Sells LLP.

Key Financial Highlights

The disclosed financial statements provide a detailed breakdown of the company’s performance. The standalone unadjusted financial results show a profit before tax of ₹5,299.87 Lakhs for the quarter ended September 30, 2026, and a total comprehensive income of ₹4,714.72 Lakhs. Consolidated figures indicate a profit before tax of ₹11,041.05 Lakhs and a total comprehensive income of ₹8,274.11 Lakhs for the same period.

Fund Utilisation Statement

An accompanying Statement of Deviation/Variation in the utilization of funds raised through Qualified Institutional Placement (QIP) has also been provided as Annexure B. This statement details the original objects for which funds were raised and the subsequent utilisation, indicating no deviation in the use of funds raised.

Annexures Included

The filing includes Annexure A, which contains the unaudited standalone and consolidated financial results along with the limited review report. Annexure B provides the statement of deviation or variation in fund utilization.

Source: BSE

Previous Article

Molbio Diagnostics reports Q2 FY27 unaudited financial results